Please login to the form below
cHL
This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.
Keytruda doubles five-year survival rate in NSCLC
Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer,
Latest news
-
Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC
Tyvyt has also been approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma (cHL).
-
Keytruda hits primary endpoint in confirmatory lymphoma trial
CHL is, in comparison to Keytruda’s other indications, not quite as important. ... That includes evaluating Keytruda in combination with chemotherapy in children and young adults in first-line cHL and in the post-Adcetris treatment setting.
-
Innovent gears up for PD-1 inhibitor launch in China
cHL) in December.
-
China’s BeiGene takes PD-1 antibody into pivotal trials
The single-arm trial enrolled 70 cHL patients who had failed autologous stem cell transplantation (ASCT) – a primary treatment for the cancer – or were ineligible for the procedure.
-
Merck suspends two Keytruda trials after patient deaths
Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
